Litcius/Paper detail

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

George R. Painter, Michael G. Natchus, Oren J. Cohen, Wendy Holman, Wendy Painter

2021Current Opinion in Virology176 citationsDOIOpen Access PDF

Topics & Concepts

PandemicCoronavirus disease 2019 (COVID-19)Antiviral drugDrug developmentBiologyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Alphavirus2019-20 coronavirus outbreakVaccinationCoronavirusIntensive care medicineBetacoronavirusAntiviral treatmentImmune systemDrugImmunologyVirusMedicinePharmacologyOutbreakInfectious disease (medical specialty)DiseasePathologyChronic hepatitisSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchViral gastroenteritis research and epidemiology
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19 | Litcius